Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology
                  1.1. Information Procurement
                  1.2. Information or Data Analysis
                      1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                  3.1. Disease Primer and Epidemiology
                      3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Ovarian Cancer Drugs Market Overview
                  4.1 Major Therapeutic Classes for Ovarian Cancer
                  4.2 Market, by Therapeutic Class
                  4.3 Sales Performance, by Therapeutic Class (2016 - 2022)
                      4.3.1. PARP Inhibitors
                      4.3.2. Angiogenesis Inhibitors
                      4.3.3. PD-L1 Inhibitors
                  4.4 Market Size and Forecast (2016- 2022)
                  4.5 Market Size and Forecast, by Seven Major Markets (2016- 2022)
                      4.5.1 U.S., Sales by Therapeutic Class (2016 - 2022)
                      4.5.2 U.K., Sales by Therapeutic Class (2016 - 2022)
                      4.5.3 Germany, Sales by Therapeutic Class (2016 - 2022)
                      4.5.4 France, Sales by Therapeutic Class (2016 - 2022)
                      4.5.5 Italy, Sales by Therapeutic Class (2016 - 2022)
                      4.5.6 Spain, Sales by Therapeutic Class (2016 - 2022)
                      4.5.7 Japan, Sales by Therapeutic Class (2016 - 2022)
                  4.6 Market Share Distribution, by Company (2016- 2022)
                  4.7 Market Dynamics and Brand Strategies
                  4.8 Patent Expiry Analysis
                  4.9 Ovarian Cancer Market: Drivers and Restraints
                      4.9.1 Market Drivers
                      4.9.2 Market Restraints
                  4.10. M&A, Deal Landscape (2013-2017 YTD)
                      4.10.1 Mergers & Acquisitions
                      4.10.2 Deals Landscape
                  4.11. Evolution of Biosimilars
                  4.12. Emerging Markets
                  4.13. Pricing and Reimbursement Scenario
                  4.14. Ovarian Cancer Sector SWOT
Chapter 5 Ovarian Cancer Drugs Market: Pipeline Intelligence
                  5.1. Pipeline Landscape
                      5.1.1 Leading Drugs in Development
                      5.1.2 Key R&D Trends
                  5.2 Key R&D Trends
                  5.3 Pipeline Landscape
                      5.3.1 Late Stage Pipeline and Sales Forecast
                  5.4 Clinical Profiles of Disruptive Drugs
                  5.5 Global Pipeline Forecast
Chapter 6 Company Profiles
                  6.1 AstraZeneca
                      6.1.1 Company Overview
                      6.1.2 Current Product Portfolio
                      6.1.3 Product Forecast Sales Through 2022
                      6.1.4 Strategic Initiatives
                          6.1.4.1 Key Company News Flow
                      6.1.5 Pipeline Analysis & Overview
                      6.1.6 SWOT
                  6.2 Roche/ Genentech
                      6.2.1 Company Overview
                      6.2.2 Current Product Portfolio
                      6.2.3 Product Forecast Sales Through 2022
                      6.2.4 Strategic Initiatives
                          6.2.4.1 Key Company News Flow
                      6.2.5 Pipeline Analysis & Overview
                      6.2.6 SWOT
                  6.3 Tesaro
                      6.3.1 Company Overview
                      6.3.2 Current Product Portfolio
                      6.3.3 Product Forecast Sales Through 2022
                      6.3.4 Strategic Initiatives
                          6.3.4.1 Key Company News Flow
                      6.3.5 Pipeline Analysis & Overview
                      6.3.6 SWOT
                  6.4 Clovis Oncology
                      6.4.1 Company Overview
                      6.4.2 Current Product Portfolio
                      6.4.3 Product Forecast Sales Through 2022
                      6.4.4 Strategic Initiatives
                          6.4.4.1 Key Company News Flow
                      6.4.5 Pipeline Analysis & Overview
                      6.4.6 SWOT
Chapter 7 Market Outlook
                  7.1 What the Future Holds
                  7.2 The Winners and Losers
                      7.2.1 Winners
                      7.2.2 Losers
                  7.3 Emerging Companies & Technology Platforms
                  7.4 The Road Ahead

List of Tables

TABLE 1 Stages of Ovarian Cancer and Five-Year Survival Rate
TABLE 2 Type of Patients based on Response to Platinum-based Chemotherapy
TABLE 3 Epidemiology of Ovarian Cancer (2016)
TABLE 4 Marketed Drugs for Ovarian Cancer
TABLE 5 Sales by Therapeutic Class, in $ million, 2016 - 2022
TABLE 6 PARP Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 7 Angiogenesis Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 8 PD-L1 Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 9 Sales Performance by Geographic Markets, in $ million, 2016 - 2022
TABLE 10 U.S. Sales by Drug Class (2016 - 2022)
TABLE 11 U.K. Sales by Drug Class (2016 - 2022)
TABLE 12 Germany, Sales by Drug Class (2016 - 2022)
TABLE 13 France, Sales by Drug Class (2016 - 2022)
TABLE 14 Italy, Sales by Drug Class (2016 - 2022)
TABLE 15 Spain, by Drug Class (2016 - 2022)
TABLE 16 Japan, Sales by Drug Class (2016 - 2022)
TABLE 17 Patent Expiry Analysis
TABLE 18 Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 19 R&D Pipeline Overview – Leading Drugs
TABLE 20 Late Stage Pipeline Analysis
TABLE 21 Bavencio (avelumab)
TABLE 22 VB-111 (ofranergene obadenovec)
TABLE 23 Tecentriq (atezolizumab)
TABLE 24 IMGN853 (mirvetuximab soravtansine)
TABLE 25 Pipeline Forecast
TABLE 26 AstraZeneca Product Forecast Sales (2016 - 2022)
TABLE 27 Roche Product Forecast Sales (2016 - 2022)
TABLE 28 Tesaro Product Forecast Sales (2016 - 2022)
TABLE 29 Clovis Oncology- Product Forecast Sales (2016 - 2022)

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 U.S. - Ovarian Cancer Incidence and Mortality Trends
FIG. 8 U.S. - Age Standardized Trends for Ovarian Cancer
FIG. 9 EU5 Ovarian Cancer Incidence Trends
FIG. 10 U.K. - Ovarian Cancer Incidence and Mortality Trends
FIG. 11 Germany - Ovarian Cancer Incidence and Mortality Trends
FIG. 12 Therapeutic Class, Market Share Distribution, 2016 - 2022
FIG. 13 PARP Inhibitors, Market Share Distribution, 2016 - 2022
FIG. 14 Market Size, by Country, 2016 - 2022
FIG. 15 Market Shares Distribution, by Company (2016 - 2022)
FIG. 16 India- Ovarian Cancer Prevalence Trends
FIG. 17 Ovarian Cancer Sector SWOT
FIG. 18 AstraZeneca Ovarian Cancer Sales Forecast
FIG. 19 AstraZeneca SWOT Analysis
FIG. 20 Roche Ovarian Cancer Sales Forecast
FIG. 21 Roche SWOT Analysis
FIG. 22 Tesaro Ovarian Cancer Sales Forecast
FIG. 23 Tesaro SWOT Analysis
FIG. 24 Clovis Oncology Ovarian Cancer Sales Forecast
FIG. 25 Clovis Oncology SWOT Analysis